2-[2-[4-(3-Methoxypropoxy)phenyl]-1,3-thiazol-4-yl]propan-2-ylcarbamic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-[2-[4-(3-Methoxypropoxy)phenyl]-1,3-thiazol-4-yl]propan-2-ylcarbamic acid
• 英文别名: 2-[2-[4-(3-methoxypropoxy)phenyl]-1,3-thiazol-4-yl]propan-2-ylcarbamic acid
• 化学式: C₁₇H₂₂N₂O₄S
• 分子量: 350.4
• InChiKey: JKLWLIQMMJAJNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] METHODS FOR TREATING PROTEINOPATHIES<br/>[FR] PROCÉDÉS DE TRAITEMENT DE PROTÉINOPATHIES
  申请人：GENZYME CORP

  公开号：WO2016145046A1

  公开（公告）日：2016-09-15

  This disclosure relates to a method of treating a proteinopathy in a subject, the method comprising administering to the subject an effective amount of a quinuclidine compound. The disclosure also relates to a method of reducing, reversing or preventing the accumulation of protein aggregates in tissue of a subject diagnosed as having a proteinopathy, or being at risk of developing a proteinopathy, the method comprising administering to the subject an effective amount of a quinuclidine compound. Also disclosed is a pharmaceutical composition comprising a quinuclidine compound for use in said methods. The proteinopathy may be a synucleinopathy or a tauopathy, such as Parkinson's disease, Alzheimer's disease or dementia with Lewy bodies.

  这份披露涉及一种治疗受试者蛋白病的方法，该方法包括向受试者施用有效量的环丙胺化合物。该披露还涉及一种减少、逆转或预防被诊断为患有蛋白病或有患蛋白病风险的受试者组织中蛋白聚集物积累的方法，该方法包括向受试者施用有效量的环丙胺化合物。还披露了一种包含环丙胺化合物的药物组合物，用于上述方法。蛋白病可能是突触核蛋白病或tau蛋白病，如帕金森病、阿尔茨海默病或带有Lewy小体的痴呆症。
• [EN] GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] INHIBITEURS DE SYNTHASE DE GLUCOSYLCÉRAMIDE
  申请人：GENZYME CORP

  公开号：WO2014043068A1

  公开（公告）日：2014-03-20

  The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.

  该发明涉及抑制葡萄糖鞘氨醇合成酶（GCS）的抑制剂，用于治疗代谢性疾病，如溶酶体贮积病，单独或与酶替代疗法、囊性疾病以及癌症的联合治疗。
• Glucosylceramide synthase inhibitors
  申请人：Genzyme Corporation

  公开号：US11008316B2

  公开（公告）日：2021-05-18

  The invention relates to inhibitors of glucosylceramide synthase (GCS), such as Compound of Formula I, shown below, as defined herein, useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.

  本发明涉及葡萄糖酰胺合成酶（GCS）的抑制剂，例如下图所示的式 I 化合物，如本文所定义的，可用于治疗代谢性疾病，如溶酶体贮积症，可单独使用或与酶替代疗法、囊性疾病联合使用，也可用于治疗癌症。
• GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
  申请人：Genzyme Corporation

  公开号：EP2895484A1

  公开（公告）日：2015-07-22
• METHODS FOR TREATING PROTEINOPATHIES
  申请人：Genzyme Corporation

  公开号：EP3267983A1

  公开（公告）日：2018-01-17